Fresenius SE & Co. KGaA
http://www.fresenius.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Fresenius SE & Co. KGaA
40+ Candidates Give US FDA Plenty Of Latitude While Growing 2023 Novel Approval Count From 2022
User fee goal dates in the second half of 2023 suggest cancer and breakthrough therapy approvals should recover from first-half dips and a resumption of inspections in China could revive COVID-delayed products.
Finance Watch: Venture Capital Funders Raise Billions For Biotech Investments
Private Company Edition: Forbion closed two funds totaling €1.35bn ($1.5bn) and Glide Healthcare raised €600m ($657.5m) for its latest fund, joining recent venture capital raises by Lux Capital and Wellington Management, but in the first quarter biopharma VC company financings fell dramatically.
Keeping Track: Pharming’s Joenja, Cidara’s Rezzayo And Incyte’s Zynyz Headline US FDA Approval Bonanza
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Finance Watch: Another VC Mega-Round As Flare Raises $123m Series B
Private Company Edition: Flare Therapeutics, targeting transcription factors to discover precision medicines, had big pharma backing for its second venture capital financing. Also, Mediar closed a $10m series A round, Switch launched with $52m and EpiBiologics raised a $50m series A round.
Company Information
- Industry
- Distributors
- In Vitro Diagnostics
- Medical Devices
- Pharmaceuticals
- Services
- Other Names / Subsidiaries
-
- APP Pharmaceuticals, Inc.
- Asia Renal Care Ltd.
- Fresenius Kabi Pharmaceuticals Holding, Inc.
- Fresenius Medical Care
- Fresenius Medical Group AG
- Vifor-Fresenius Medical Care Renal Pharma Ltd. (VFMCRP)
- Xenios AG
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice